Current Patent Expiry for Canakinumab
Canakinumab (Ilaris), Novartis's IL-1β inhibitor for rare autoinflammatory diseases and gout flares, faces no approved biosimilars yet. Key U.S. patents expire between 2023 and 2030, with the latest composition-of-matter patent (US 7,829,093) ending May 2030. European patents largely expired in 2023, but regulatory data exclusivity blocks biosimilar approvals until at least 2026 in the EU.[1][2]
When Do Major Patents Expire?
- U.S.: Primary patents expired 2023-2025 (e.g., US 6,337,072 in September 2023), but method-of-use and formulation patents extend to 2028-2030. A key patent challenge by Alvotech was dismissed in 2023, upholding protection.[2][3]
- EU: Data exclusivity ends March 2026; several patents expired December 2023, opening Paragraph IV challenges.[1]
- Japan: Exclusivity runs to 2026, with patents to 2030.[2]
No biosimilars launch before 2026 anywhere due to these barriers. Earliest U.S. entry likely post-2030 if litigation clears.
Biosimilar Pipelines Targeting Canakinumab
Several developers are advancing:
- Alvotech (AVT02): Filed U.S. BLA in 2023; FDA accepted but paused pending patent settlement. Targets 2026+ launch.[3]
- Samsung Bioepis/Biogen: Phase 3 trials completed; U.S. filing expected 2024-2025, aiming for post-2030.[2]
- Intas/Momenta: U.S. and EU filings in progress; launch eyed for 2027-2028 in EU if approved.[1][2]
- Celltrion and others: Early-stage candidates in India/China, but U.S./EU entry delayed by patents.
At least 5-7 programs globally, but none commercialized yet.[2]
Factors Delaying Biosimilar Entry
Patent thickets (20+ U.S. patents listed) trigger litigation under BPCIA, often adding 2-5 years. Manufacturing complexity for this monoclonal antibody raises immunogenicity risks, slowing approvals. Novartis settled some challenges, blocking generics until 2030+.[3] Market size (~$1B peak sales) incentivizes competition, but low volume for rare indications limits urgency.
How Does This Compare to Similar Biologics?
| Drug | Brand | Key Patent Expiry | First Biosimilar Entry |
|------|-------|-------------------|-----------------------|
| Adalimumab | Humira | 2023 | 2023 (Amjevita, etc.) |
| Etanercept | Enbrel | 2029 | Expected 2029 |
| Canakinumab | Ilaris | 2030 | Expected 2030+ |
| Ustekinumab | Stelara | 2025 | 2025 (Wezlana) |
Canakinumab trails due to unresolved disputes, unlike adalimumab's flood of 10+ biosimilars post-patent cliff.[2][4]
Pricing Impact from Biosimilars
U.S. list price ~$1,500/dose now; biosimilars could cut 20-40% initially, more if multiple entrants. EU tenders already pressure pricing post-2023 expiries.[1]
[1]: DrugPatentWatch.com - Canakinumab Patents
[2]: FDA Purple Book - Ilaris
[3]: Alvotech v. Novartis Litigation Update
[4]: IQVIA Biosimilars Report 2024